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ABSTRACT
The membrane-associated matrix metalloproteinase-14, MT1-MMP, has been 
implicated in pericellular proteolysis with an important role in cellular invasion of 
collagenous tissues. It is substantially upregulated in various cancers and rheumatoid 
arthritis, and has been considered as a potential therapeutic target. Here, we report 
the identification of antibody fragments to MT1-MMP that potently and specifically 
inhibit its cell surface functions. Lead antibody clones displayed inhibitory activity 
towards pro-MMP-2 activation, collagen-film degradation and gelatin-film degradation, 
and were shown to bind to the MT1-MMP catalytic domain outside the active site 
cleft, inhibiting binding to triple helical collagen. Affinity maturation using CDR3 
randomization created a second generation of antibody fragments with dissociation 
constants down to 0.11 nM, corresponding to an improved affinity of 332-fold with 
the ability to interfere with cell-surface MT1-MMP functions, displaying IC50 values 
down to 5 nM. Importantly, the new inhibitors were able to inhibit collagen invasion 
by tumor-cells in vitro and in vivo primary tumor growth and metastasis of MDA-
MB-231 cells in a mouse orthotopic xenograft model. Herein is the first demonstration 
that an inhibitory antibody targeting sites outside the catalytic cleft of MT1-MMP can 
effectively abrogate its in vivo activity during tumorigenesis and metastasis.
INTRODUCTION
Membrane-type 1 matrix metalloproteinase (MT1-
MMP) is a type I transmembrane proteinase thought to 
be a major effector of pericellular proteolysis in a wide 
range of cell types [1]. The ability of MT1-MMP to 
cleave various extracellular matrix (ECM) components, 
including types I, II and III collagens, fibrin, and laminin 
1 and 5, reflect its potential activities during cell invasion 
of ECM. Further, it can regulate cell signaling functions 
in response to the changing pericellular environment by 
the modulation of cell surface receptors, such as the αv 
and α5 integrins and the ectodomains of syndecan and 
CD44, as well as some growth factors. MT1-MMP can 
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also initiate proteolytic cascades by activating other MMPs, 
including pro-MMP-2, pro-MMP-8 and pro-MMP-13 [2– 4]. 
MT1- MMP over-expression has been detected in tumor 
cells and adjacent stromal cells in a variety of human tumors 
and has been correlated with poor clinical outcomes [5, 6]. 
Numerous studies of tumor cells and cancer-associated 
stromal cells have demonstrated an unequivocal role in 
the ability of a number of cell types to invade the ECM 
[7–9]. In angiogenesis, the fibrinolytic and collagenolytic 
activities of MT1-MMP are directed to the sprouting 
tip of endothelial cells as they invade the surrounding 
ECM [10, 11]. In a 3D tumor model, we showed that 
MT1-MMP activity was required for neo-angiogenesis 
not only by endothelial cells, but also by associated 
fibroblasts [12]. The pro-angiogenic effects of MT1- MMP 
have additionally been ascribed to up-regulation of 
VEGF-A via activation of a Src/Akt kinase-dependent 
signaling pathway [13]. MT1-MMP is an effector of 
synovial pannus invasion and destruction of cartilage in 
Rheumatoid Arthritis [14].  It drives the migration and 
function of autoreactive T-cells [15] and of macrophages 
in peripheral nerve injury [16], suggesting that this 
pericellular protease plays significant role in a number of 
pathological processes and should be considered a viable 
target for therapeutic interventions.
It is broadly known that therapeutic targeting 
of members of the MMP family demands greater 
specificity of MMP inhibitors. The recent development 
of newer generations of more specific inhibitors [17] has 
demonstrated that MMPs that are more unambiguously 
implicated in pathological processes could indeed be 
good therapeutic targets. However, small molecule 
inhibitors directed at the highly homologous active sites 
of MMPs are inevitably less specific, and the concept 
of targeting extra-catalytic motifs determining substrate 
specificity may be a useful approach [18]. Therapies 
with human recombinant antibodies also represent a 
significant alternative to small molecule-based targeted 
therapies in cancer treatment [19]. MT1-MMP has been 
a successful target in this respect [20], and a number of 
antibodies targeting extra catalytic sites of this protease 
have been described [21–23]. We have refined this 
concept using antibody maturation techniques via CDR3 
randomization and re-selection to fine-tune the isolation of 
potent antibody derivatives against MT1-MMP exosites. 
Furthermore, since there is a notable discrepancy in the 
in vitro efficacy of inhibitors against a soluble form of 
the enzyme and the activity at the surface of cells, we 
have utilized cell-based screening techniques to isolate 
inhibitors that demonstrate substantial in vivo efficacy.
RESULTS
Isolation of scFv antibodies inhibiting MT1-MMP 
With the aim of generating specific potent antibodies 
capable of inhibiting MT1-MMP function at the cell-
surface, we chose to target epitopes outside the highly 
conserved catalytic cleft. The recombinant full ectodomain 
of pro-MT1-MMP E240A, which lacks proteolytic activity 
due to the substitution of the active site glutamate with 
alanine, was used as the target antigen for selection of 
binding scFvs from a naïve human scFv phage-display 
library [24]. N-terminal sequencing confirmed that the 
pro-domain of recombinant pro-MT1-MMP E240A was 
still present and therefore occluding the catalytic cleft. 
Solution phase selection was carried out using biotinylated 
pro-MT1-MMP E240A antigen and streptavidin-coated 
agarose beads, which thus pulled down antibody fragment 
clones binding to pro-MT1-MMP. Clones chosen for 
further analysis were selected based on the presence of 
unique heavy and light chain CDR3 sequences and strong 
binding in ELISA. MT1-MMP inhibitory properties of 
selected clones were evaluated using a macromolecular 
substrate cleavage assay. Fibrillar collagen type I was 
incubated with the active form of recombinant wt 
MT1- MMP in the presence or absence of purified scFv’s 
and the cleavage products analyzed using SDS-PAGE. As 
shown in Figure 1A, collagen is cleaved progressively with 
increasing MT1-MMP concentration. In the presence of 
individual scFv’s clones, collagen cleavage was inhibited 
to varying degrees up to 100% inhibition (Figure 1B). As 
controls, the general hydroxamate-based MMP inhibitor 
CT1746 showed full inhibition, whereas a negative control 
antibody fragment (against intracellular desmin; Fc- scFv 
DES) exhibited no inhibition. Selected MT1- MMP 
binding scFv’s were further characterized using a 
fluorogenic peptide substrate assay. As shown in Figure 2, 
addition of scFv’s  did not inhibit MT1-MMP activity in 
the absence of TIMP-2, confirming that selected scFv’s 
bind to MT1-MMP outside the catalytic cleft. Some scFv’s 
were found to inhibit the binding of TIMP-2 to the active 
MT1-MMP. MT1-MMP activity was almost completely 
inhibited in the presence of 10-fold excess TIMP-2 in 
the absence of scFv’s, but pre-incubation of MT1-MMP 
with several scFv’s protected MT1-MMP from TIMP-2 
inhibition (exemplified by scFv-1, Figure 2) The same 
scFv’s outcompeted the N-terminal fragment of TIMP-3 
(N-TIMP-3) from binding to MT1-MMP, showing that it 
was the N-terminal part of the TIMP molecule that was 
competed away (data not shown). We thus screened scFv 
antibodies using these two macromolecular screening 
approaches and narrowed down the initially selected 
scFv's to 27 inhibitory clones. 
Assessment of functional properties of lead 
antibodies using assays dependent on cell-
membrane bound MT1-MMP activity 
To identify scFv antibodies inhibiting the catalytic 
activity of cell-surface MT1-MMP, we reformatted 
them into Fc-scFv formats for improved stability and 
analyzed their ability to interfere with endogenously 
expressed MT1-MMP on HT-1080 cells. First, the effect 
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on degradation of fluorescent-labeled gelatin (F-gelatin) 
films by HT-1080 cells was examined (Figure 3A, left 
panel) and we confirmed that gelatin film degradation 
activity in HT1080 cells is due to MT1-MMP activity 
(data not shown). As a result, three clones, E3, G1 and 
C2, were found to inhibit fluorescent-labeled gelatin 
film degradation, with the most potent being E3 
(Figure  3A, right panel). Many of the lead Fc-scFv’s 
were not inhibitory, however two antibodies strongly 
stimulated gelatin film degradation (E10, Figure 3A). 
Figure 1: MT1-MMP scFv’s selected for the ability to prevent collagen cleavage. (A) Aliquots of ectodomain MT1-MMP (50, 
20, 10, 5 or 0 nM) were incubated with fibrillated collagen type I for 16 hours at room temperature. The reaction products were analyzed 
by reducing SDS-PAGE. Collagen cleavage was observed as the conversion of the Mr ~100 kDa bands of collagen type I to the Mr~75 kDa 
¾-fragments. (B) In separate reactions, ectodomain MT1-MMP was pre-incubated with E.coli. supernatant containing scFv-antibodies 
selected to MT1-MMP. As indicated by stars, some scFv’s were identified as possible hits for interfering with MT1-MMP catalyzed 
collagen cleavage. In lanes indicated by numbers, MT1-MMP was pre-incubated with control Fc-scFv DES (1), with CT1746 (2) or sample 
without MT1-MMP (3). 
Figure 2: MT1-MMP scFv’s selected for the ability to interfere with interactions to TIMP-2. Selected scFv’s were screened 
for the ability to compete with TIMP-2 for MT1-MMP binding. The activity of ectodomain MT1-MMP towards a small fluorogenic peptide 
substrate was inhibited by TIMP-2, but not by selected scFv’s (scFv 1 and 2). However, the TIMP-2 inhibition could be competed away by 
some scFv’s (scFv-1), but not by others (scFv-2), as indicated in the figure.   
Oncotarget16776www.impactjournals.com/oncotarget
A broad- spectrum hydroxamate-based MMP inhibitor, 
GM6001, completely inhibited gelatin-film degradation, 
whereas control Fc-scFv DES showed no effect 
(Figure 3A, right panel, GM6001 acts in a similar manner 
to CT1746 and the two were used interchangeably). Next, 
the effect of lead Fc-scFv antibodies on cell-surface 
collagenolytic activity of MT1-MMP was evaluated using 
HT-1080 cells. GM6001 completely inhibited collagen 
degradation by endogenous MT1-MMP. Fc- scFv E3, 
G1 and C2 were inhibitory, with E3 showing the most 
potent inhibition of collagenolytic activity (Figure 3B). 
E10 Fc- scFv did not show noticeable effect on collagen 
degrading activity (Figure 3B). Next, the effect of 
Fc-scFv’s on cell surface pro-MMP-2 activation was 
examined. HT-1080 cells were cultured in the presence 
of Fc-scFv’s and culture media were analyzed by gelatin 
zymography. As shown in Figure 4A, the Fc-scFv 
antibodies E3 and G1 potently inhibited pro-MMP-2 
activation, while other clones showed no inhibitory 
activity. E10 had no effect on pro-MMP-2 activation, and 
GM6001 completely inhibited the activation. Since Fc-
scFv E3 and G1 could also compete with TIMP-2 binding 
to MT1-MMP, the inhibitory mechanism of pro-MMP-2 
activation might be dual; displacing TIMP-2 from cell-
surface MT1-MMP that would normally serve as receptor 
for bringing pro-MMP-2 to active free MT1-MMP and/or 
sterically hindering interactions between free MT1- MMP 
and its macromolecular substrate pro-MMP-2. In conclusion, 
two Fc-scFv antibodies, E3 and G1, displayed inhibitory 
activity towards all three cell-surface MT1-MMP functions 
whereas Fc-scFv C2 showed a minor effect on gelatinolytic 
and collagenolytic MT1-MMP activity.
Lead Fc-scFv antibodies display orthosteric 
inhibition by binding to the MT1-MMP catalytic 
domain outside the catalytic cleft 
Given that E3 showed the most potent inhibition of 
cell-surface MT1-MMP, we investigated the mechanism 
behind this in greater detail. Initially, we evaluated 
the effect of E3 on the activation of pro-MT1-MMP 
(containing the pro-domain) by furin. Recombinant 
pro-MT1-MMP could be activated by furin over time, 
as visualized on SDS-PAGE. However, in the presence 
of Fc-scFv E3, no delay of pro-MT1-MMP activation 
by furin could be observed (Figure 4B), indicating that 
the observed functional effect of E3 was not due to 
inhibition of pro-MT1-MMP activation cleavage. Also, 
western blotting analysis of MT1-MMP from cell lysates 
of Fc-scFv E3 treated HT-1080 cells did not reveal 
any differences in MT1-MMP in terms of the amount 
of enzyme or its activation status compared to other 
selected antibodies or negative antibody control treatment 
(Figure 4C). We next examined the E3 binding site of 
MT1-MMP using recombinant forms of the individual 
domains. The binding affinity (KD) of Fc-scFv E3 for the 
isolated catalytic domain of MT1-MMP was determined 
to be 22.4 ± 14.5 nM using surface plasmon resonance 
(SPR) analysis, which is comparable to that of the 
ectodomain (KD 36.5 ± 5.3 nM), whereas no binding to 
the isolated hemopexin domain was observed. In addition, 
pre-incubating 20 nM MT1-MMP catalytic domain with 
250 nM TIMP-2 abolished binding to E3, whereas pre-
incubating MT1-MMP with the active site-oriented small 
molecule hydroxamate inhibitor, CT1746, did not (data 
not shown).
Next, we investigated the effect of E3 on the 
ability of MT1-MMP to bind type I collagen. The data 
indicated that the binding of MT1-MMP to the collagen 
was decreased by Fc-scFv E3 in a dose-dependent manner. 
Interestingly, when a triple helical collagen peptide 
spanning 7–17′ of the collagen II cleavage site [25, 26] 
was used instead of full length collagen type I, the binding 
of MT1-MMP was not outcompeted (Figure 5). Thus, 
ligands binding directly in the active site, such as the 
hydroxamate inhibitor, CT1746 or the small fluorogenic 
peptide substrate, or likely the collagen peptide, are not 
affected by E3, whereas binding of larger ligands such 
as collagen type I and TIMP-2 is abrogated. We thus 
concluded that the Fc-scFv E3 is an orthosteric antagonist 
since it competes with the MT1-MMP interaction with 
macromolecular substrates.
Lead Fc-scFv antibodies are specific for  
MT1-MMP
We next examined the specificity of the E3 and G1 
Fc-scFv antibodies using a TIMP-competition assay in 
which a number of proteinases were assayed by hydrolysis 
of a small fluorogenic peptide substrate in the presence 
of either TIMP-2 or TIMP-3. When using either the 
ectodomain or the catalytic domain of MT1- MMP, the 
inhibition observed by both TIMP-2 and TIMP-3 was 
reversed by the Fc-scFv E3 and G1, but not by control DES 
(Figure 2 and Supplementary Figure 1). We confirmed that 
no such effect of the Fc-scFv’s was observed when using 
MT2-MMP, MT3-MMP, MT5-MMP, MMP-1, MMP-2, 
MMP-3, MMP-7, MMP-9, MMP-10, MMP-13, MMP-19, 
MMP-26 and ADAM17 inhibited by either TIMP-2 or -3 
(Supplementary Figure 1).
Improving lead Fc-scFv’s antibodies to 
generate variants with high binding affinity and 
inhibitory potency
Given that Fc-scFv E3 and G1 displayed inhibitory 
activity against several activities of cell-surface MT1-
MMP, we decided to further improve their affinity using 
an affinity maturation technique. For each of the two 
Fc-scFv’s, new phage-display libraries were prepared 
focusing on the CDR3 loop of both the heavy and light 
chains, since these loops usually are central to antigen 
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binding. Kunkel mutagenesis was employed to obtain 
variant antibody fragments, with blocks of 5–6 amino 
acid residues in the CDR3 loops being randomized to 
yield a total of 5 and 6 new phage libraries for E3 and 
G1, respectively, and with a diversity of up to 6.4 × 107 
amino acid combinations for each new library. In affinity 
selections, light and heavy chain libraries were kept 
separate, and the concentration of pro-MT1-MMP E240A 
antigen was continuously decreased from 1 nM down 
to 5 pM. Subsequently, an off-rate selection round was 
carried out to select antibody scFv-fragments with the 
slowest off-rates. Thus, biotinylated MT1-MMP antigen 
was allowed to bind phage display selection outputs from 
affinity selections before a large excess of non-biotinylated 
MT1-MMP was added. Following incubations of up to 
20 h, phage-displayed antibody fragments still binding 
biotinylated-MT1-MMP were pulled down. 
To retain the original epitope binding sites as 
the parent E3 and G1 in the new antibody variants, a 
homogenous time-resolved fluorescence (HTRF) assay 
Figure 3: Lead Fc-scFv’s inhibit cell-surface MT1-MMP gelatinolytic and collagenolytic activity. HT-1080 cells were 
cultured on fluorescently-labeled gelatin (A) or collagen film (B) in the absence or presence of purified MT1-MMP Fc-scFv’s, DES control 
or GM6001. For gelatinolytic activity, cells were fixed after 18 hours and imaged. Staining of actin ensured similar cell numbers in areas 
of imaging. For collagenolytic activity, cells were fixed after 3 days of incubation and collagen stained with Coomasie Brilliant Blue. 
As exemplified by Fc-scFv E3, a few clones were able to inhibit both gelatin and collagen degradation.  Control Fc-scFv DES served as 
negative control, whereas GM6001 gave complete inhibition (A and B). 
Oncotarget16778www.impactjournals.com/oncotarget
was used to identify improved scFv clones in which 
competition of new clones with parent Fc-scFv E3 was 
measured. The parent E3 was used as reference in all 
subsequent analysis of improved variants. As shown in 
Figure 6A, a HTRF binding curve of Fc-scFv E3 parent 
to MT1-MMP was obtained by labelling E3 with a d2-
acceptor dye and using biotinylated MT1-MMP together 
with a streptavidin europium-cryptate donor. A competition 
assay was set up based on the specific E3 binding curve 
and used to monitor displacement of d2-labeled E3 parent 
by the new affinity-improved scFv-antibodies directly 
from E. coli. cultures (Figure 6B). In parallel, the TIMP-
2 competition assay was again used to identify antibody 
variants capable of competing with TIMP-2 for MT1-
MMP binding. Based on these two assays, lead affinity-
matured clones were selected from 1152 screened clones, 
reformatted into Fc-scFv, expressed and purified, and 
tested in the TIMP-2 competition assay with increasing 
Fc-scFv concentrations (Figure 6C and  6D). A number of 
identified clones showed increased TIMP-2 competition 
compared to parent E3, whereas the negative control 
Fc- scFv DES showed no competition (Figure 6C and 6D). 
Importantly, the affinity improved Fc-scFv variants 
showed no binding to homologous proteases when 
analysed in the same TIMP competition assay as above 
for parent E3 and G1 (data not shown).
Figure 4: Fc-scFv’s inhibit activation of pro-MMP-2, but not activation of pro-MT1-MMP. (A) For pro-MMP-2 activation 
assays, HT-1080 cells were cultured in the presence of trace amounts of collagen type I in the absence or presence of MT1-MMP Fc-scFv’s 
or GM6001. Following 18 hours of incubation, cell culture supernatant was analysed for levels of pro-MMP-2 and active MMP-2 by 
zymography. A few lead Fc-scFv’s displayed inhibitory activity as shown by E3 and G1, while the majority did not, as exemplified by E10. 
The experiments shown are representative of a total of three independent experiments. (B) Full ectodomain Pro-MT1-MMP was incubated 
with or without furin, and in the presence or absence of DES Fc-scFv control or E3, as indicated, for 3 hours at RT. Reaction products were 
analyzed by reducing SDS-PAGE, and conversion of pro-MT1-MMP to MT1-MMP by furin was observed. (C) Analysis of HT1080 cell 
lysates for the presence of MT1-MMP was carried out by Western blotting using anti-MT1-MMP polyclonal antibody N175/6. As a loading 
control, actin was detected by rabbit anti-actin polyclonal antibody.
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Figure 5: Fc-scFv's compete with collagen type I for binding to MT1-MMP whereas binding of collagen peptide 
is unaffected. In an ELISA setup, pepsin-extracted collagen type I or collagen peptide were coated in wells after which ectodomain 
MT1- MMP was allowed to bind in the absence or presence of Fc-scFv E3 or DES control antibody at a concentration of 0-500 nM. 
Figure 6: Affinity maturation of lead antibody clones and screening for improved variants. Homogeneous time-resolved 
fluorescence (HTRF), TIMP-2 competition and surface plasmon resonance assays were utilized to identify affinity improved variants of 
lead Fc-scFv’s. (A) In HTRF assays, parent E3 binding to MT1-MMP was observed by direct labeling of E3 and detection with labeled 
streptavidin and biotinylated full ectodomain pro-MT1-MMP. (B) The ability to outcompete labeled parent Fc-scFv E3 from binding to 
MT1-MMP was detected as a decrease in HTRF signal and displayed as percent of total fluorescence in the absence of competing scFv. 
(C) Cleavage of small fluorogenic peptide by ectodomain MT1-MMP was inhibited by TIMP-2. E3 Fc-scFv E3 outcompeted TIMP-2 
inhibition of MT1-MMP, as shown by increasing E3 concentrations from 0–400 nM. (D) The efficacy of improved variants to outcompete 
TIMP-2 from ectodomain MT1-MMP was directly compared to E3 parent. 
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Kinetics of affinity matured MT1-MMP Fc-scFv’s
To directly evaluate whether the 2nd generation 
E3 and G1 clones possessed an increased affinity to 
MT1- MMP, SPR was employed using the Fc-scFv 
format of each antibody. New variants showed both faster 
association and slower dissociation rates, and Table I 
summarizes the binding kinetics for the new variants 
compared to parent E3 and G1. The increase in binding 
affinity was up to 20- and 70-fold for E3 and G1 variants, 
respectively, with the highest binding clones being C6 
(KD 1.88 nM) and E2 (KD 0.92 nM). In addition, Fc-scFv 
E2 was immobilized directly to a sensor chip and used 
for competition analysis by measuring the binding to 
MT1-MMP alone or to MT1-MMP pre-complexed with 
antibodies. As expected, parent E3 competed with the 
MT1-MMP binding (data not shown). 
From the sequencing of 384 new variant clones 
selected from activity screening, it was evident that for 
the G1 lineage, the best performing variants were almost 
exclusively changed in the heavy chain CDR3 (Table 1). 
The same trend was found for the E3 lineage, however 
more variant clones from this parent were found to be 
changed in the light chain CDR3, such as the highest 
affinity clone C6. The light chain of C6 was therefore 
combined with different heavy chain variants of E3 and 
with the heavy chain of the best G1 lineage clone E2. 
Surprisingly, the combination between the C6 light chain 
and the E2 heavy chain, named E2_C6, was functional 
and clearly more active than each of the variants alone, 
showing a KD of 0.11 nM, corresponding to a 332-fold 
increased binding affinity compared to the E3 parent 
(Figure 6D and Table I). Interestingly, the two cysteines 
present in the G1 parent heavy chain CDR3 were 
conserved in all new G1 variants, indicating that these 
two residues are required to preserve binding affinity, 
potentially forming a closed loop structure of the CDR3.   
Effects of improved Fc-scFv’s on cell-surface 
MT1-MMP activities
Since fluorescent-labeled gelatin film degradation 
and pro-MMP-2 activation assays were readily quantifiable, 
we used these two assays to directly evaluate the inhibitory 
potential of the improved Fc-scFv antibodies. As shown 
in Figure 7A and 7B, improved variants A4_7 (E3 
lineage) and E2_C6 (mixed E3 and G1 lineage) showed the 
highest potency, with IC50 values between 3 nM and 25 nM 
in the two assays. The general MMP inhibitor CT1746 
showed complete inhibition whereas no inhibition was 
observed with control Fc-scFv DES (Figure 7A and 7B). In 
addition, fluorescent-labeled gelatin degradation by COS-
7 cells overexpressing mouse MT1-MMP was inhibited 
by both E2_C6 and A4_7 showing that these Fc-scFv’s 
are cross-reactive between human and mouse MT1-MMP 
(Supplementary Figure 2). Importantly, non-transfected 
COS-7 cells showed no degradation of fluorescent-labeled 
gelatin. We examined the effect of E2_C6 on cell-free 
gelatin cleavage using the catalytic domain of MT1-
MMP. Although not showing full inhibition of gelatin 
degradation at the concentrations used, there was a clear 
inhibitory effect with maximal inhibition of 50 nM MT1-
MMP achieved with 100–200 µM E2_C6. The Fc-scFv 
DES control showed no activity whereas GM6001 showed 
full inhibition (Supplementary Figure 3).
We used an inducible MT1-MMP overexpressing 
variant of HT-1080, HTC-75 [27] to evaluate the effect 
of Fc-scFv’s on the level of CD44 shed from the cell 
surface by MT1-MMP. This cell line displays a low level 
of endogenous CD44 shedding in part due to MT1-MMP 
activity, but substantial over-expression is achieved by 
removal of tetracycline [27, 47]. The inhibition of both 
endogenous and exogenous MT1-MMP thus demonstrates 
the cell-surface inhibitory potential of the antibodies. 
HTC-75 cells cultured in the presence of MT1-MMP-
specific Fc-scFv’s showed a decreased level of CD44 in the 
conditioned medium compared to a negative Fc-scFv DES 
control, whereas CT1746 showed near complete inhibition 
(Figure 7C). The IC50 values for the best performing Fc-
scFv’s A4_7 and E2_C6 were around 100 nM. As a final 
measure of cell-surface MT1-MMP activity, we examined 
the effect of antibodies on transwell collagen invasion 
by HT1080 cells. Fc-scFv A4_7, E2 and C6 showed full 
inhibition at 500 nM (data not shown). Fc-scFv E2_C6 
was tested at different concentrations and, as shown in 
Figure 7D, displayed near 100% inhibition at 19 nM.  
Anti-MT1-MMP Fc-scFv’s inhibit primary 
tumor growth and metastasis development
Next we investigated the ability of the two selected 
Fc-scFv’s E2_C6 and A4_7 to inhibit primary tumor 
growth in vivo. To select between different relevant tumor 
cell lines, we analyzed the levels of MT1-MMP using both 
an ELISA and Western blotting analysis. MDA-MB-231 
breast cancer cells, with and without LUC2, contained 
substantial amounts of MT1-MMP and compared to other 
cell lines tested, a significantly higher amount of active 
MT1-MMP without pro-domain (Supplementary Figure 4). 
Thus, MDA-MB-231 LUC2 breast cancer cells were 
inoculated into the mammary fat pad of immunodeficient 
mice. At day four after cancer cell implantation mice were 
treated with E2_C6 (n = 8, 5 mg/ kg), A4_7 (n = 8, 5 mg/ kg) 
or control DES (n = 8, 5 mg/kg) i.p. three times per week 
for ten weeks. After seven weeks the primary tumors were 
surgically removed and tumor volume calculated. The size 
of the primary tumors were significantly reduced by more 
than two-fold after treatment with E2_C6 (p < 0.01) and 
A4_7 (p < 0.001) when compared to treatment with DES 
(Figure 8A). Cross sections of the primary tumors also 
demonstrated the difference in tumor growth between the 
three treatment groups (Figure 8B).  
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After surgical removal of the primary tumors, the 
animals were imaged weekly to quantify the development 
of lung and axillary lymph node metastasis by measuring 
the luciferase signal from metastatic tumor cells in the 
thoracic region using an IVIS Spectrum instrument 
(Figure 8C). Ten weeks after cancer cell transplantation, 
A4_7 and E2_C6 treated mice had significantly reduced 
metastasis compared to control DES-treated mice 
(Figure 8D). Macroscopic histological analysis identified 
axillary lymph node metastases in 4/7 animals treated 
with DES, 0/5 of the E2_C6 treated animals and 1/7 of 
the A4_7 treated animals. A more detailed investigation 
of the inhibition of lung metastasis was performed using 
immunohistochemical stainings for human cancer cells 
of randomly chosen lung sections from each mouse. No 
metastasis or single human cancer cells were observed in 
the mice treated with E2_C6, and thus calculation of the 
relative area of metastases showed that E2_C6 treatment 
significantly inhibited lung metastasis development 
compared to DES treatment (Figure 8E). Reduced amounts 
of lung metastasis (both in numbers and size) was also 
observed in animals treated with A4_7 compared to those 
treated with DES (Figure 8F and Supplementary Figure 5), 
although the difference did not reach statistical significance 
when comparing the relative area of metastases. To 
identify the mechanism underlying the difference in size 
of the primary tumors and the metastasis in mice treated 
with MT1-MMP Fc-scFv’s versus those treated with 
control Fc-scFv DES, we examined the morphology of 
primary tumors and metastasis. The primary tumors of 
the controls were larger, but appeared morphologically 
similar to the MT1-MMP Fc-scFv-treated tumors, both 
having a central necrotic area. The ratio between vital 
tumor tissue and necrotic tissue were similar for the two 
groups. For both type of tumors, the border between vital 
tumor tissue and necrotic tissue contained apoptotic cells, 
as determined by an antibody against cleaved caspase 3 
(Supplementary Figure 6). No difference in the number 
of apoptotic cells was observed between the two groups. 
The primary tumors and lung metastasis were also stained 
for collagen using Sirius Red stain. The primary tumors 
contained very small amounts of collagen surrounding 
the relatively few blood vessels within the tumors. For 
the lung metastasis, the MT1-MMP Fc-scFv-treated 
animals contained few and small metastases and exhibited 
normal size collagen layers around the bronchia and blood 
vessels. The animals treated with control Fc-scFv DES 
exhibited higher numbers and much larger metastases, 
and several metastases involved blood vessels where the 
collagen layer was significantly thinned or almost missing 
(Supplementary Figure 7).
DISCUSSION
The concept of inhibitors targeting exosites 
of metzincin metalloproteinases, to gain specificity 
of action with respect to individual proteases and 
even specific substrates is a consequence of the close 
homology of their Zn containing active site clefts [28]. 
The development of low molecular weight Zn binding 
inhibitors over some decades has been hampered by 
this similarity. Although there are currently a number 
of more specific inhibitors of this type, most have a 
rather broad range of action with consequent problems 
Table 1: Sequence and kinetic binding constants for selected anti-MT1-MMP Fc-scFv’s
Clone CDR3 heavy chain CDR3 light chain
kon (×104)
(M−1s−1)
koff (×10−4)
(s−1) KD (nM)
KD(parent)/ 
KD(new)
E3 parent FAGREGESDI QQSYSTPST 2.34 ± 0.51 8.4 ± 0.9 36.5 ± 5.3 1
A2 FWGNLGESDI QQSYSTPST 1.50 ± 0.71 2.3 ± 0.2 16.6 ± 6.4 2.2
A4_7 FSPPPGESDI QQSYSTPST 13.4 ± 3.05 5.3 ± 0.7 3.99 ± 0.4 9.15
A6_5 FAVYQPWEDI QQSYSTPST 18.6 ± 14.5 4.0 ± 2.4 2.34 ±0.6 15.6
A6_2 FLPPPGESDI QQSYSTPST 43.3 ± 54.1 7.2 ± 8.2 2.21 ± 0.9 16.5
C6 FAGREGESDI LFPLSDPST 26.9 ± 26.7 3.0 ± 0.7 1.88 ± 1.1 19.4
G1 parent IGYCSGGSCSSGDYGMDV QQYNSYPLT 0.76 ± 0.51 3.5 ± 0.2 65.1 ± 48.4 1
E1 YCPGEAGSCSSGDYGMDV QQYNSYPLT 0.34 ± 0.01 1.9 ± 0.03 56.5 ± 0.8 1.15
F1 YCPVEAGSCSSGDYGMDV QQYNSYPLT 4.47 ± 1.90 1.2 ± 0.4 3.24 ± 2.3 20.1
E6 FCPFSQGSCSSGDYGMDV QQYNSYPLT 21.8 ± 22.8 1.0 ± 0.33 1.12 ± 1.0 58.1
E2 FCPLSTGSCSSGDYGMDV QQYNSYPLT 32.9 ± 11.8 3.2 ± 1.9 0.92 ± 0.2 70.8
E2_C6 FCPLSTGSCSSGDYGMDV LFPLSDPST 18.8 ± 7.95 0.2 ± 0.1 0.11 ± 0.04 332 and 592
Amino acid sequence of CDR3 loops for selected anti-MT1-MMP antibodies are shown. Surface plasmon resonance (SPR) 
was used for kinetic analysis of the binding of selected Fc-scFv’s to pro-MT1-MMP E240A. The kon, koff and KD values were 
determined by global fitting to a 1:1 binding model with the BIACORE evaluation program. KD (parent)/ KD (new) is the fold 
improvement in KD of the affinity matured variants compared to E3 and G1 respectively.
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for future applications in the treatment of human 
pathologies, as well as confusion about their precise 
targets in model studies [29]. Herein, we describe a 
strategy to identify and refine specific scFv antibodies 
that bind outside the catalytic cleft of MT1-MMP 
and effectively prevent its proteolytic functions at the 
surface of cells.
Most metzincins have domains outside the catalytic 
domain that may be involved in macromolecular substrate 
cleavage specificity, as well as functional motifs within the 
catalytic domain, but outside the active site cleft, termed 
‘exosites’. Further, there are data to show that shape 
changes, or dimer or oligomer formation can also be part 
of the macromolecular substrate cleavage process. The 
concept of targeting extra catalytic motifs is reasonable, 
but major challenges lie in the paucity of structural 
information on enzyme-substrate interactions outside the 
catalytic cleft. More detailed work on the collagenolytic 
MMPs, particularly MMP-1, has shown that the hemopexin 
domain is essential for collagenolysis, participating in the 
modulation of the triple helical structure of the substrate 
to allow access to the catalytic cleft [26]. Interestingly, 
Remacle and colleagues [30] targeted the hemopexin 
domain of MT1-MMP to isolate suitable inhibitors 
from a library of small ligands from the Developmental 
Therapeutics Program (DTP) National Cancer Institute/
NIH collection. Using a site formed by β-strands 1 of 
blades I to IV of the hemopexin domain of MT1-MMP, 
distinct from the dimerization interface defined by the 
crystal structure [31], compound docking simulations 
Figure 7: Affinity-improved Fc-scFv’s effectively inhibit cell-surface MT1-MMP activity. (A) HT-1080 cells were cultured 
in the presence of trace amounts of collagen type I, and in the absence or presence of MT1-MMP Fc-scFv’s (0–400 nM), DES control 
(400 nM) or GM6001 (10 µM). Following 18 hours of incubation, cell culture supernatant was analyzed for levels of pro-MMP-2 
and active MMP-2 by zymography. Quantification of active MMP-2 levels was done by densitometric analysis of inverted images. 
(B) HT-1080 cells were cultured on fluorescent-labeled gelatin in the absence or presence of MT1-MMP Fc-scFv’s (0–200 nM), DES 
control Fc-scFv DES (200 nM) or GM6001 (10 µM). Cells were fixed after 18 hours and imaged. Quantification of gelatin degradation was 
done by densitometric analysis of inverted images. (C) HTC-75 cells were cultured in the absence or presence of MT1-MMP Fc-scFv’s 
(0–1000 nM), DES control (1000 nM) or GM6001 (10000 nM). Following 15 hours of incubation, cell culture supernatant was analyzed 
for levels of CD44 shedding by ELISA. (D) Effect of Fc-scFv E2-C6 (0–500 nM), Fc-scFv DES control (500 nM) or GM6001 (10 µM) in 
a collagen invasion assay in which HT-1080 cells were allowed to invade through the collagen matrix for 24 hours towards cell medium 
containing fetal calf serum as attractant. 
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Figure 8: Anti-MT1-MMP A4_7 and E2_C6 Fc-scFv's inhibit primary tumor growth and spontaneous metastasis 
development in mice. MDA-MB-231 LUC2 cells (106) were transplanted into the mammary fat pad of CB-17 SCID mice. A4-7 Fc-
ScFv, E2_C6 Fc-ScFv or control DES Fc-ScFv (all at 5 mg/kg) were administered at day four and subsequently three times per week 
for 10 weeks. (A) Calculated tumor volumes after seven weeks were compared between the three treatment groups using ANOVA and 
Turkeys multi-comparison tests, (**p < 0.01, ***p < 0.001). (B) Cross sections of the primary tumors from the three different treatment 
groups.  (C) After surgical removal of the primary tumors, the animals were imaged for potential lung and axillary lymph node metastasis 
development by measuring luciferase activity in the thoracic region using an IVIS Spectrum instrument. (D) Endpoint measurements 
(10 weeks after initiation of treatment) of photon radiance per area were compared between the three treatment groups using the Kruskal-
Wallis and Dunn’s multi-comparison test (*p < 0.05). (E) Lung metastasis development was compared between the three treatment groups 
by calculating the relative metastasis area immunohistochemically stained for human vimentin of randomly chosen sections of mouse 
lungs. (F) Immunohistochemical stainings of mouse lungs from the three treatment groups showing regions with the most extensive 
metastasis development. Arrows depict metastatic foci. 
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were carried out, followed by biochemical and cell-based 
screening assays to detect potential interacting/inhibitory 
compounds. They identified a novel compound that 
interfered with homodimerisation of MT1-MMP but had 
no inhibitory activity in small fluorescent peptide substrate 
assays. The compound inhibited tumor cell migration 
on collagen and effectively repressed tumor growth in 
an in vivo mouse model, confirming that the dimer form 
of MT1-MMP was necessary for optimal cell surface 
function [32] Similarly, synthetic peptides mimicking the 
outermost strand motifs within the hemopexin domain 
of MT1-MMP defined as essential for homo/hetero 
dimerisation were shown to specifically inhibit MT1-
MMP-enhanced cell migration, although the ability to 
directly prevent MT1-MMP proteolytic activity was not 
shown [33]. Furthermore, these peptides interfere with 
cancer metastasis without affecting primary tumor growth. 
Antibodies as inhibitors of metzincin metallo-
proteinases have also been used to screen for relevant extra 
catalytic motifs. We have previously developed effective 
inhibitory antibodies to the disintegrin, cysteine-rich 
(Dis- Cys) domain of human ADAM17, as well as a cross-
domain antibody binding, in addition to the Dis-Cys domain, 
to  catalytic domain exosite(s) [34]. Further, an inhibitory 
antibody to an exosite motif in murine and human ADAM17 
was isolated [35]. Larkin and colleagues developed an 
antibody to ADAMTS5 that cross-links the active site 
and the disintegrin domain that was more effective than 
binding the active site alone [36]. An antibody to the motif 
Trp116 to Lys214 outside the Zn binding site of MMP-9 
was shown to be an effective inhibitor that functioned 
both in vitro and in vivo [37]. A monoclonal antibody 
that recognizes the ‘MT-loop’ structure, an eight residue 
insertion in the catalytic domain specific for MT–MMPs 
and distant from the MT1–MMP active site, was developed 
by Ingvarsen and colleagues and shown to prevent tissue 
inhibitor of metalloproteinases-2 (TIMP-2) association 
with MT1–MMP [38] The antibody thus incapacitates the 
TIMP-2-dependent MMP-2-activating function alone rather 
than the general enzymatic activity and the pro-migratory 
function of MT1–MMP [22, 39]. Another antibody to the 
MT-loop was shown to inhibit HT1080 cell invasiveness by 
preventing localization of MT1-MMP to the focal adhesion 
complex without affecting its proteolytic activity [40]. These 
effects may be compared with a monoclonal antibody to a 
peptide describing the MT-loop originally prepared by the 
Arroyo group. A recent crystal structure of its interactions 
with MT1 MMP has shown that conformational swiveling 
of the surface MT-loop is required for effective binding 
and consequent inhibition of MT1-MMP activity on the 
cell membrane. This inhibition mechanism appears to 
effectively control active MT1-MMP in endothelial cells and 
at the leading edge of migratory cancer cells [23]. 
Phage display libraries are powerful tools to identify 
a repertoire of different antibody binding motifs in 
target antigens. The consequent antibodies are amenable 
to improvements by both engineering or maturation 
techniques, as well as subsequent large-scale production 
as recombinant proteins [41]. In the case of MT1-MMP, an 
inhibitory antibody fragment (DX-2400; Ki = 0.6 nM for 
human MT1-MMP; IC50 ~ 1–5 nM) was developed using 
a human Fab library and the MT1-MMP catalytic domain 
as antigen [20]. This antibody can be inferred to interact 
with the active site cleft since it inhibited small fluorescent 
peptide hydrolysis. It was found to inhibit MDA-MB-231 
primary tumor growth and metastasis in xenograft mouse 
models, although problems with in vivo stability have been 
reported [18]. 
In the quest for suitable therapeutic entities, 
we set out to examine whether additional inhibitory 
specificity might be gained by targeting extra catalytic 
motifs of MT1-MMP in screens of highly versatile 
antibody fragment libraries displayed on bacteriophages. 
Previously, we described a recombinant human scFv 
antibody against the hemopexin domain of MT1-MMP 
derived from the screening of a V-gene library [21]. 
The lead scFv modulated MT1-MMP interactions with 
collagen, and was weakly inhibitory in an isolated collagen 
fibril assay. In cell-based studies, it did not inhibit MT1-
MMP-mediated pro-MMP-2 activation but effectively 
prevented cell degradation of collagen or gelatin films and 
cell membrane CD44 shedding. Further, it was found to 
be an effective inhibitor of the invasive capacity of cancer 
cells and of angiogenesis in model systems [12, 21], but 
no in vivo experiments were performed. 
In the study described herein, we used a more 
powerful phage display library reported to yield antibodies 
with high affinity and diversity [24, 42, 43], screening 
against the full ectodomain of pro-MT1–MMP. With the 
propeptide blocking the active site cleft, we searched 
for antibodies binding outside the conserved active site. 
Our approach focused on identifying antibody fragments 
that were effective inhibitors of cell-surface MT1-MMP. 
Instead of targeting a specific domain of MT1-MMP, 
the phage library was subjected to the ectodomain and 
the screening for inhibitory clones was directed towards 
MT1- MMP on the surface of living cells as early as 
possible with the specific aim of isolating scFv antibodies 
that effectively inhibit a range of cell-associated 
MT1- MMP proteolytic events. It has been reported that 
compounds to cell-membrane proteases displaying low 
nanomolar inhibition in biochemical assays are much less 
potent inhibitors of their cell-membrane-bound target [44], 
stressing the importance of early screening towards the 
true cell-membrane-bound target molecule. Biochemical 
assays with small and macromolecular substrates for 
MT1- MMP showed that the lead Fc- scFv E3 did not 
interfere directly with small substrate or inhibitor binding 
to the active site cleft. Instead, lead Fc-scFv’s interfered 
with the binding of macromolecular substrates and 
inhibitors to the catalytic domain. This was exemplified by 
Fc- scFv inhibition of catalytic domain-TIMP-2 interactions 
and gelatin degradation by the MT1- MMP catalytic 
domain [32], showing that Fc-scFv’s act as orthosteric 
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antagonists competing with the enzyme interactions to 
macromolecular substrates. 
However, the lack of binding competition between 
selected lead Fc-scFv’s and one MT1-MMP ligand used 
in this study, a triple helical collagen peptide, is more 
difficult to interpret. This peptide binds both the active 
site cleft and the hemopexin domain of MMP1 (DB133) 
[25, 26] and is also known to bind MT1-MMP (B. Basu, 
M.Rapti and G.Murphy; unpublished). Thus, the collagen 
peptide likely spans a larger region of the MT1-MMP 
surface as on MMP-1, but is not competed away by the 
presence of Fc-scFv E3.  
Having identified several lead clones, we proceeded 
to utilise a maturation process to enhance their affinity. 
Since highly diverse CDR3 loops have been reported as 
the key determinant of specificity in antigen recognition 
[45], we carried out affinity selections using our most 
potent first generation scFv clones E3 and G1. New VH 
and VL libraries were constructed via randomizing blocks 
of five to six amino acid residues in the CDR3 loops 
[35, 46]. Using affinity selections with steadily decreasing 
antigen levels in addition to off-rate selection with a 
large excess of non-biotinylated antigen, antibodies with 
changes in the CDR3 loops that decreased the dissociation 
rate and increased overall binding strength were favoured. 
Since first-generation antibody fragments were selected 
for their ability to inhibit cell-surface MT1- MMP 
activity, screening for 2nd generation higher affinity 
antibody fragments was carried out such that the binding 
epitope and inhibition mechanism was preserved. Thus, 
a homogenous time-resolved fluorescence assay using 
competition with parent Fc-scFv E3 as measure was used 
in combination with the ability to compete with TIMP- 2 
for MT1-MMP binding. The finally selected mature 
clones were assessed for their activity in cell-associated 
MT1-MMP assays and found to be active against pro-
MMP-2 activation, gelatinolysis, collagenolysis (HT1080 
cell migration) and CD44 shedding [47]. The inhibitory 
activity towards cell-surface pro-MMP-2 activation 
might be a combined effect of sterically interfering with 
MT1- MMP interactions with both TIMP-2, functioning as 
a pro-MMP-2 activation ‘receptor’, and the pro- MMP- 2 
substrate. In addition to these cell-surface effects, E2_
C6 inhibited cell-free gelatin degradation catalyzed 
by catalytic domain MT1- MMP. We conclude that the 
motif(s) targeted by our Fc-scFv’s therefore represent 
a common interaction site(s) for a number of different 
macromolecular substrates and that the site(s) are 
localized in the catalytic domain outside the active site 
cleft. A hypothesis on the epitope localization can be 
inferred based on both of the following two parameters; 
residues that differ between MT1-MMP and MT2-MMP 
and residues within the proximity of the MT1-MMP-
TIMP-2 interaction site. By protein sequence alignment 
of MT1- MMP and MT2-MMP and from inspection of 
the crystal structure of the complex between TIMP-2 and 
MT1-MMP [Protein Data Bank accession 1BQQ], the 
following amino acids were identified as potential epitope 
residues: I114L, Q115T, L117R, A165E, Y166D, E169L, 
G170R, H171R, E172Q, Q174E, E183S, T190S, E195T, 
N208G, I209L, S217A, A218D, N229H, D252N, S254N, 
M264K and await future structural validation. 
The two most active Fc-scFv antibodies were tested 
in an MDA-MB-231 tumor model using CB-17 SCID 
mice and found to slow tumor growth significantly and 
to completely abrogate the development of metastases. 
This is similar to the work of Zarrabi et. al. [33], wherein 
peptides binding the MT1-MMP hemopexin domain 
prevented MDA-MB-231 metastases, but had little effect 
on primary tumor growth.
Thus, targeting extra-catalytic domain motifs 
using an antibody library represents a novel approach 
for the inhibition of MT1-MMP-mediated cellular 
proteolysis.  Given the role of this enzyme in cell invasive 
processes associated with cancer, rheumatoid arthritis, 
atherosclerosis and diabetes, future rigorous testing of the 
antibodies in a wide range of pathological models should 
be investigated. This will allow further evaluation of the 
importance of MT1-MMP mediation in the migration of 
different cell types driving various disease processes and 
determine the shape of novel therapeutic strategies.
MATERIALS AND METHODS
Proteins and reagents
Variants of MT1-MMP; pro-MT1-MMP E240A 
(full ectodomain of MT1-MMP containing the pro-
domain, residues 21–541 and with the E240A mutation); 
MT1-MMP wild-type (wt) without pro-domain (residues 
112–541, ectodomain); wt MT1-MMP catalytic domain 
(residues 112–285); and wt MT1-MMP hemopexin 
domain (residues 316–508) were expressed in Escherichia 
coli BL21 (DE3) pLysS (Invitrogen), refolded from 
inclusion bodies and purified using ion exchange 
chromatography (HiTrapQ FF, GE healthcare) followed 
by gel filtration (for pro-MT1-MMP E240A). Pro-
MT1-MMP E240A was analyzed by N-terminal Edman 
sequencing to confirm presence of pro-domain. Pro-MT1-
MMP E240A was biotinylated using biotin-xx-microscale 
protein labeling kit (B30010, Invitrogen) following 
manufactures recommendations. The degree of labeling 
was estimated to be 1–2 molecules of biotin/molecule 
of enzyme (FluoReporter Biotin Quantitation Assay 
Kit, Invitrogen). MT2-MMP, MT3-MMP, MT5-MMP, 
MMP- 1, MMP-2, MMP-3, MMP-7, MMP-9, MMP- 10, 
MMP-13, MMP- 19, MMP-26 were available from R & D 
and ADAM17 produced in-house [34]. TIMP-2 and 
TIMP-3 with C-terminal His-tag was expressed in E. coli, 
folded in vitro and purified [48]. The triple helical collagen 
II peptide DB133 was a kind gift of Richard Farndale, 
Biochemistry, Univ. Cambridge, UK [25]. Unless stated 
otherwise, all chemicals were purchased from Sigma-
Aldrich. The hydroxamate inhibitor GM6001 was from 
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EMD Millipore (Temecula, CA, USA) and CT1746 was 
a gift from UCB/Celltech, Slough UK.
Phage display selections
A naïve human scFv phage-display library [24] 
was used for selection of MT1-MMP binding antibodies. 
Initially, the library was pre-incubated with streptavidin-
beads (Dynal beads, Invitrogen) to remove phages 
recognizing the beads before being exposed to 100 nM 
of biotinylated pro-MT1-MMP E240A. Streptavidin-
beads were used to retrieve phages displaying antibody 
fragments binding to biotinylated pro-MT1-MMP E240A. 
Following two rounds of solution-phase selection, the 
eluted polyclonal scFv population was cloned into the 
pSANG10–3F expression vector for Escherichia coli 
BL21 (DE3) bacterial expression of scFv [49]. Individual 
clones (total of 960) were isolated and expressed in 96-
well format and culture supernatants directly tested for 
specific MT1-MMP binding by ELISA screening (See 
M & M on ELISA below). The 192 clones showing 
highest specific ELISA signal were sequenced and further 
evaluated for inhibitory activity. 
VH and VL CDR3 randomized library generation 
and phage selection
For affinity maturation of lead candidate antibody 
fragments, E3 and G1, the VH and VL CDR3 loops were 
randomized in blocks of 5–6 amino acid residues using 
kunkel mutagenesis as previously described [35, 46, 50]. 
In brief, uracil-containing ssDNA (dU-ssDNA) encoding 
the parental E3 or G1 with stop codons was purified from 
M13 phage using the QIAprep spin M13 kit (Qiagen). 
Primers encoding the desired randomized region were used 
to generate covalently closed circular double-stranded 
heteroduplex DNA (ccc-ds(U)DNA) consisting of wt 
and mutated DNA. The ccc-ds(U)DNA were transformed 
into DH5α cells leading to degradation of the wt DNA 
strand. Subsequent sequencing showed an average of 
approximately 70% of clones being mutated in the desired 
region. To increase the fraction of mutated sequences, a 
method incorporating  rolling cycle amplification favouring 
the mutated DNA was utilized. The final library DNA was 
PCR purified (Fermentas GeneJet PCR purification kit) 
and transformed into freshly prepared electrocompetent 
TG1 cells that were spread on Bioassay plates. The size 
of each library was between 2 × 109 and 8 × 109 covering 
the theoretical diversity of approximately 1 × 109 DNA 
molecules. Library DNA was sequence confirmed showing 
that nearly 100% of clones were mutated. For phage 
display selections, dsDNA mutant phagemid libraries were 
rescued directly from the TG1 cells.
During phage display selections, VH and VL libraries 
were kept separate. Titrated concentrations (from 10 to 
0.05 nM) of biotinylated human pro-MT1-MMP E240A 
were exposed to the CDR3 randomized VH-/VL-libraries. 
Three rounds of affinity solution-phase selection were 
carried out before 1 round of off-rate selection on which 
binding of antibody phages to biotinylated pro-MT1-
MMP E240A was allowed to reach equilibrium (2 hour 
incubation) before addition of a 100-fold excess of non-
biotinylated human pro-MT1-MMP E240A. Binding 
reactions were then allowed to proceed for 1, 5 and 
20 hours. Fast-dissociating antibody fragments would most 
likely re-bind non-biotinylated MT1-MMP and therefore 
not be selected when using streptavidin-beads.  Following 
affinity and off-rate selections, eluted polyclonal 
scFv populations were cloned into pSANG10- 3F and 
transformed into Escherichia coli BL21(DE3) for 
expression along with parental scFv-E3 and scFv-G1. A 
total of 1152 new scFv clones were individually selected 
and expressed in E. coli, and the culture supernatants 
used directly for screening using quenched-fluorescent 
peptide cleavage assay and homogenous time-resolved 
fluorescence (HTRF) assay (See M & M below).
Antibody formatting and expression
Antibodies were used in either the scFv or the Fc-
scFv format, as indicated. For scFv-fragments, expression 
was carried out using the pSANG10-3F vector and 
Escherichia coli BL21(DE3) cells [49], and the scFv-
fragments were used from the culture supernatant directly 
or from the periplasmic extract with purification by Ni-
NTA (Generon). For Fc-scFv antibodies, the heavy and 
light chains were cloned into pBioCAM5 and transfected 
into HEK-293E suspension cells for mammalian cell 
expression, as described [49]. Antibody fragments 
were purified from conditioned media using protein 
A Sepharose CL-4B (Invitrogen) or Ni-NTA agarose 
(generon) and AKTA FPLC affinity chromatography (GE 
Healthcare). Fc-scFv antibodies were dialysed into 50 mM 
Tris, 150 mM NaCl, 10 mM CaCl2, pH 7.4 (TNC) and 
filter-sterilized.
Collagen type I cleavage assay 
For screening of antibody fragments towards 
inhibition of MT1-MMP catalyzed collagen cleavage, 
scFvs were individually expressed using Escherichia 
coli BL21 (DE3) in 10 mL auto-induction media. 
Periplasmic fractions were affinity-purified by Ni-NTA 
Agarose (Qiagen) [51] followed by buffer-exchange 
into 50 mM Tris, 150 mM NaCl, 10 mM CaCl2, pH 7.4 
with 0.05% Brij35 (TNC-Brij) using 96-well Zeba 
spin filter plates (Thermo Scientific). Collagen type I 
fibrils were formed by incubation at 35oC, 2 hours and 
scFv antibodies were pre-incubated with 20 nM active 
MT1-MMP (residues 112–541) for 30 minutes, room 
temperature (RT). Fibrillar collagen was mixed with 
pre-incubated MT1-MMP/scFv and allowed to react for 
16 hours at RT before being analysed by SDS-PAGE. 
From an initial screening of 192 clones, those showing 
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inhibition of collagen cleavage were expressed at a 
50 ml scale, purified as above, and re-tested using a fixed 
concentration of 1.5 µM scFv. As controls, anti-desmin 
antibody (Fc-scFv DES) (1.5 µM), CT1746 (10 µM) and 
no MT1-MMP was used.
ELISA for initial scFv antibody screening, 
collagen-MT1-MMP binding and detection of 
MT1-MMP levels in cell lysates
For initial ELISA screening of monoclonal 
antibody fragments binding to MT1-MMP, Streptavidin 
in PBS was added to Nunc MaxiSorpTM plates (Nunc) 
for overnight incubation at 4°C. Plates were blocked 
with 3% BSA in TNC for 1 hr at RT and washed 3 times 
in TNC with 0.1% Tween-20 (TNC-T), then 3 times 
in TNC before biotinylated pro-MT1-MMP E240A 
(3 µg/ml) in TNC with 1.5% BSA was added. Culture 
supernatants from bacterial expression containing scFv 
antibodies were diluted 2-fold in 2xTNC with 3% BSA 
and applied directly to the ELISA plates. Following 
1 hour incubation and wash as above, binding of 
antibodies was detected with anti-FLAG europium in 
TNC with 1.5% BSA using time-resolved fluorescence 
spectroscopy.
For detecting MT1-MMP binding to collagen in 
the presence of Fc-scFv’s using ELISA, collagen type 
I (13 mg/ml) and collagen peptide DB133 (5 mg/ ml) 
[26] were diluted 1000-fold in TNC (collagen 
type I) and in 10 mM acetic acid (collagen peptide) 
and applied to Nunc MaxiSorpTM plates (Nunc) for 
overnight incubation at RT. Plates were blocked with 
3% BSA in TNC-T and washed in TNC-T before 25 nM 
biotinylated pro-MT1-MMP E240A in the absence or 
presence of E3 Fc-scFv (0–500 nM) or DES Fc-scFv 
(500 nM) was added and allowed to bind collagen 
for 30 minutesat RT. Plates were washed 3 times in 
TNC-T, and binding of MT1-MMP to collagen was 
detected using HRP-streptavidin diluted in TNC-T and 
3, 3′, 5, 5′-Tetramethylbenzidine (TMB) substrate with 
absorbance measured at 450 nm.
To detect levels of MT1-MMP in cell lysates from 
human cancer cell lines, polyclonal rabbit anti-MT1-MMP 
(epitomics 2010–1) was diluted 200-fold in 100 mM 
Na2CO3, pH 9.6 and applied to wells of Nunc MaxiSorp
TM 
plates (Nunc). To avoid MT1-MMP activity in ELISA, 
10 µM CT1746 was applied to all subsequent steps. Plates 
were blocked in TNC-T with 3% BSA and cell extracts 
(extraction buffer: 0.1 M tris, pH 8.1 m 10 mM EDTA, 
0.5% triton X-100) was diluted 10-fold into TNC-T before 
being applied to plates. After 3 times wash in TNC-T, 
MT1-MMP was detected with polyclonal sheep anti-MT1-
MMP N175/6 and donkey-anti-sheep-HRP using TMB 
substrate and absorbance measured at 450 nm.   
Quenched-fluorescent peptide cleavage assay 
with and without TIMP
Initial screening of scFv antibodies in quenched-
fluorescent peptide cleavage assays was carried out using 
scFv antibodies purified from 10 ml Escherichia coli 
BL21 (DE3) cultures as described above. For affinity-
matured scFv antibody screening, culture supernatants 
were used directly without purification but with a 200-
fold final dilution into the assay buffer TNC-brij. Assays 
were performed with 0.5–2 nM MT1-MMP pre-incubated 
alone or in the presence of scFv or purified Fc-scFv 
antibodies, as indicated. Cleavage of the fluorogenic 
peptide substrate Mca-KPLGL-Dpa-AR-NH2 (1 µM)
(SMO-3670-PI, Peptides International) in the presence 
or absence of 15 nM TIMP-2 was followed by excitation 
at 320 nm and emission recorded at 405 nm in a Tecan 
Infinite-200, at 37°C.
To examine specificity of inhibitors, 0.5–20 nM 
of each proteinase (MT1-MMP catalytic domain or 
ectodomain, MT2-MMP, MT3-MMP, MT5-MMP catalytic 
domain, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, 
MMP-10, MMP-13, MMP-19, MMP-26 and ADAM17) 
were pre-incubated with a final of 200 nM of Fc-scFv 
antibodies for 30 minutes at RT.  TIMP-2 or TIMP-3 with 
1 µM Mca-KPLGL-Dpa-AR-NH2 substrate were then 
added and peptide cleavage performed as above.  
Homogeneous time-resolved fluorescence 
(HTRF) assay
Initially, parent antibody Fc-scFv E3 was labeled 
with d2-acceptor per manufacturer’s recommendations 
(d2-labeling kit, Cisbio) to obtain 2–3 d2 molecules/
molecule Fc-scFv E3. A HTRF standard curve of d2-Fc-
scFv E3 binding to biotinylated pro-MT1-MMP E240A 
(0.01–200 nM) was prepared using streptavidin europium 
cryptate donor (Cisbio) and the HTRF signal was read 
using excitation at 340 nm and emission at 620 (donor) 
and 665 (acceptor). HTRF competition assays were carried 
out using a mix of 0.5 nM biotinylated pro-MT1-MMP 
E240A and streptavidin europium cryptate pre-incubated 
with 8-fold diluted Escherichia coli BL21 (DE3) culture 
supernatant containing mutated scFv antibodies. Following 
30 minutes of incubation at RT, 3 nM d2-labelled parent 
Fc-scFv E3 was added and HTRF signal read as above. 
Controls were non-labeled E3 parent and DES.
Pro-MT1-MMP activation assay
Pro-MT1-MMP E240A (2 µM) was preincubated 
with Fc-scFv’s (3 µM) for 30 minutes, RT, in 100 mM 
HEPES, 10 mM CaCl2, 0.5% triton X-100, before 1 unit 
of furin (NEB) was added. After 3 hours at 30oC, products 
were analyzed by non-reducing SDS-PAGE. 
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Surface plasmon resonance analysis
Surface plasmon resonance (SPR) analyses were 
performed on a BIACORE T100 instrument using CM5 
sensor chips and a buffer of 30 mM Hepes, 135 mM 
NaCl, 10 mM CaCl2 with 0.1% BSA and 0.05% Tween 
20 (running buffer). Affinities of the Fc-scFv’s for wt 
or various forms of MT1-MMP were determined by 
pre-capturing the Fc-scFv’s on anti-human Fc (GE 
Healthcare), immobilized to 10000 RU, by injecting 5 µl 
of 50 nM Fc-scFv antibody. The protease (0.1–200 nM) 
was thereafter injected for 120 seconds followed by a 
dissociation of 600 seconds and with a flow rate of 30 µl/
min. Binding of the Fc-scFv’s to preformed complexes 
between MT1-MMP wt catalytic domain (50 nM) and 
TIMP-2 (1 µM) or CT1746 (10 µM) was carried out in 
the same manner as above. To confirm kinetics of E2_C6 
showing slow dissociation, a single-cycle set-up was 
utilized in which increasing concentrations of MT1-MMP 
were injected over captured E2_C6 as above, but with only 
one dissociation phase of 7200 seconds. To ensure a stable 
chip surface between cycles, one concentration of protease 
was injected at least twice for each antibody or protease 
variant. The kon, koff and KD values were determined by 
global fitting to a 1:1 binding model with the BIACORE 
evaluation program.   
Gelatin and collagen film degradation assay
Cell-based MT1-MMP-dependent gelatin film 
degradation assay was carried out as described previously 
[52]. Briefly, HT1080 cells were cultured on coverslips 
coated with AlexaFluor488 -labelled gelatin (F-gelatin) in 
the presence or absence of Fc-scFv’s or GM6001 (10 µM). 
After 18 hours of incubation, cells were fixed with 3% 
paraformaldehyde in PBS and stained with Alexa Fluor 
568 phalloidin (Invitrogen), and DAPI (4′, 6-diamidino-2-
phenylindole) (Invitrogen). Coverslips were imaged with 
fluorescent microscopes using objective lens of 10×. Areas 
of fluorescent-labeled gelatin degradation were observed 
as black zones on green background. Areas of degradation 
were analyzed using Volocity software (Perkin-Elmer). 
For cell-free gelatin degradation, gelatin was 
incubated with or without 50 nM catalytic domain 
MT1-MMP and in the presence of E2-C6 (0–200 nM), 
DES (200 nM) or GM6001 (10 µm). After incubation, 
the reaction products was analysed by SDS-PAGE. For 
quantifying gelatin degradation, the gelatin fragment of 
35 kDa was used and analyzed by densitometry.
The collagen-film degradation assay was carried out 
as described previously [52]. Briefly, pepsin-extracted type 
I collagen (PureCol, advanced Biomatrix) was neutralized 
and then thinly coated onto 12-well culture plates. After 
incubation at 37oC for three hours, HT1080 cells were 
seeded on the collagen film in the presence or absence of 
Fc-scFv’s or GM6001 (10 µM). After 3 days incubation, 
cells were removed by trypsin to reveal collagen film. 
Remaining collagen were fixed with paraformaldehyde 
and stained with Coomassie Brilliant Blue. Areas of 
collagen degradation were observed as white zones on 
blue background under widefield microscopy.
Cellular Pro-MMP-2 activation assay 
HT1080 cells in 12-well plates were treated with 
100 μg/ml type I collagen (PureCol, advanced Biomatrix) 
in serum-free media in the presence or absence of Fc-
scFv’s or GM6001 (10 µM). After 3 days, conditioned 
media were analyzed for pro-MMP-2 activation by 
zymography, and cells lysates were analyzed for MT1-
MMP and actin by Western Blotting. Zymography was 
performed using Novex 10% gelatin zymogram gels 
(Invitrogen) according to manufacturers’ instructions. 
Levels of pro-MMP-2 and active MMP-2 were quantified 
using Image J.  
CD44 shedding cell assay
Tet-Off HTC-75 cells, which overexpress MT1-
MMP [47], were used for CD44 shedding assays. These 
cells were seeded in 12-well cell culture plates (Corning) 
and grown 24 hours without doxycycline to upregulate 
MT1-MMP expression. Culture media were then switched 
to serum-free DMEM in the presence or absence of Fc-
scFv’s or GM6001 (10 µM). After 15 hours, shed CD44 
in the conditioned media was analyzed by ELISA (CD44 
instant ELISA, eBiosciences) according to manufacturer’s 
instructions.
Cell invasion assay
The collagen invasion assay was performed as 
described previously with modifications [40]. Briefly, 
the upper side of 8 µm pore membranes of transwell 
chambers (Fisher Scientific) were coated with neutralized 
acid-extracted type I collagen (cell matrix type I-A, Nitta 
gelatin). In the lower chamber, media containing 10 % 
FBS with or without Fc-scFv’s or GM6001 (10 µM) were 
added. 3 × 104 HT1080 cells in serum-free medium were 
seeded on the collagen matrix of the upper chamber with or 
without Fc-scFv’s or GM6001 (10 µM). After incubation 
for 24 hours at 37oC, invaded cells appearing on the other 
side of the membrane were counted by staining cells with 
DAPI and analysing images with Volocity software.   
Western blot analysis
Analysis of cell lysates for the presence of MT1-
MMP by Western blotting  was carried out using a sheep 
anti-MT1-MMP polyclonal antibody (N175/6) [53]. As 
a loading control, actin was detected by rabbit anti-actin 
polyclonal antibody (Abcam).   
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Cell lines and culture
The MDA-MB-231 LUC2 [54] cell line was 
maintained in DMEM supplemented with 10% FBS, 
5% penicillin/streptomycin. Cultures were grown in a 
humidified atmosphere of 5% CO2 at 37°C. 
In vivo studies of anti-MT1-MMP treatment
Subconfluent MDA-MB-231 cells were washed in 
PBS and harvested using trypsin. Cells (1 × 106) were 
resuspended in a 1:1 mixture of extracellular matrix 
from the Engelbreth-Holm-Swarm sarcoma and DMEM 
before orthotopic transplantion into the mammary fat 
pad of anesthetized eight week-old female CB-17 SCID 
mice (Taconic, Ry, Denmark). E2_C6 Fc-scFv, A4_7 
Fc-scFv and control DES Fc-scFv (all at 5 mg/ kg) were 
injected i.p. four days after the transplantation (n = 8) 
and subsequently injected three times per week for ten 
weeks. Primary tumors were removed from anesthetized 
mice using blunt instrument dissection. Primary 
tumor sizes were calculated using V = (W2 × L)/2. 
All animal experiments were approved by The 
Experimental Animal Committee, The Danish Ministry 
of Justice and performed at the animal facility core 
at University of Southern Denmark. The mice were 
housed under specific pathogen-free conditions 
with ad libitum food and drinking water. The mice 
were euthanized if they showed any adverse signs or 
symptoms of disease, including weight loss, paralysis 
or general discomfort.
In vivo imaging
Relative quantification of metastasis development 
was performed weekly using whole-body bioluminescent 
imaging (IVIS-spectrum, Caliper Life Science). Mice 
were injected with D-luciferin (150 mg/kg body weight) 
and then anaesthetized with isoflurane gas. Images 
were acquired starting 10 min after luciferin injection. 
Regions of interest (ROI) were drawn to encircle the 
thoracic region to quantify lung and axillary lymph node 
metastases. The photon emission transmitted from the 
ROIs was quantified in photons/s/cm2/sr using Caliper Life 
Science Living image (version 4.2).
Immunohistochemistry
Staining procedures were performed as previously 
described [55]. For human vimentin (VimentinV9, M0725, 
Dako, 1:1000) and cleaved caspase-3 staining (ASP175, 
Cell Signaling Tech, 1:400), heat-induced epitope retrieval 
was performed by microwave boiling for 15 min in TE 
(Tris/EDTA, pH 9) buffer (Dako). Collagen staining 
was performed using Sirius Red stain and analyzed by 
polarized light microscopy.
Statistics
The statistical significance of bioluminescence 
measurements of tumor growth or metastasis in different 
groups was calculated using one-way ANOVA or Kruskal-
Wallis tests, when appropriate. To analyze the specific 
sample pairs, Turkeys or Dunn’s multi-comparison test 
were used. p-values greater than 0.05 were considered not 
significant.
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